Second Quarter 2025 Performance - Revenue increased to $5,936 million in Q2 2025, a 3.5% increase compared to $5,743 million in Q2 2024[5] - Core revenue growth was 1.5% and FX contributed 2.0% to revenue growth[5] - Adjusted diluted net earnings per common share increased by 4.7% to $1.80 in Q2 2025, compared to $1.72 in Q2 2024[5] - Adjusted operating profit margin remained flat at 27.3% in both Q2 2024 and Q2 2025[5] Segment Performance (Q2 2025) - Biotechnology revenue increased by 8.0% to $1,850 million, with core growth of 6.0% and FX contributing 2.0%[8] Adjusted operating profit margin increased by 150 BPS to 41.0%[8] - Life Sciences revenue increased slightly by 0.5% to $1,777 million, with core revenue declining by 2.5%, acquisitions contributing 1.5%, and FX contributing 1.5%[10] Adjusted operating profit margin decreased by 180 BPS to 19.3%[10] - Diagnostics revenue increased by 2.0% to $2,309 million, with core growth of 2.0%, divestitures reducing revenue by 0.5%, and FX contributing 0.5%[12] Adjusted operating profit margin decreased by 60 BPS to 26.1%[12] Guidance - The company forecasts low-single digit core sales growth for the three-month period ending September 26, 2025, compared to the same period in 2024[26] - The company forecasts 3.0% core sales growth for the year ending December 31, 2025, compared to 2024[26] - Adjusted operating profit margin is expected to be approximately 25.5% for the three-month period ending September 26, 2025[26] - Adjusted diluted net earnings per common share are projected to be between $7.70 and $7.80 for the year ending December 31, 2025[26] Cash Flow - Net cash provided by operating activities decreased by approximately 5.5% to $1,338 million for the three-month period ended June 27, 2025, compared to $1,417 million for the same period in 2024[52] - Free cash flow decreased by approximately 3.5% to $1,094 million for the three-month period ended June 27, 2025, compared to $1,131 million for the same period in 2024[52]

WASHINGTON, July 22, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a leading global life sciences and diagnostics innovator, today announced that Matthew Gugino, currently Group Chief Financial Officer of the Company's Life Sciences Innovations Group and Vice President of Financial Planning & Analysis, will succeed Matthew McGrew as Danaher's Chief Financial Officer effective February 28th, 2026. Following the transition and consistent with past practice, Mr. McGrew will continue thereafter as an Ex ...

Core Insights - Danaher Corporation reported strong second quarter results, driven by effective execution of the Danaher Business System and growth in the Bioprocessing segment [2][4] - The company anticipates continued growth in core sales and adjusted diluted net earnings for the remainder of 2025, despite a fluid macro environment [2][4] Financial Performance - For the second quarter of 2025, net earnings were $555 million, or $0.77 per diluted common share, with non-GAAP adjusted diluted net earnings per common share at $1.80 [9][12] - Revenues increased by 3.5% year-over-year to $5.9 billion, while non-GAAP core revenue grew by 1.5% [9][18] - Operating cash flow was reported at $1.3 billion, with non-GAAP free cash flow at $1.1 billion [9][20] Future Outlook - The company expects non-GAAP core revenue growth of low-single digits for the third quarter of 2025 and approximately 3% for the full year [4][18] - Adjusted diluted net earnings per common share guidance has been raised to a range of $7.70 to $7.80 for the full year, up from the previous range of $7.60 to $7.75 [4][18] Segment Performance - Total sales growth for the company was 3.5%, with the Biotechnology segment growing by 8.0%, while Life Sciences experienced a slight increase of 0.5% [18] - Core sales growth varied by segment, with Biotechnology at 6.0%, Life Sciences declining by 2.5%, and Diagnostics growing by 2.0% [18] Cash Flow and Investments - The net cash provided by operating activities was $1.338 billion, with total cash used in investing activities at $258 million [20] - Free cash flow for the quarter was reported at $1.094 billion, demonstrating the company's ability to generate cash after capital expenditures [20]

[Q2 2025 Earnings Release Overview](index=1&type=section&id=Danaher%20Reports%20Second%20Quarter%202025%20Results) Danaher reported strong Q2 2025 results with $5.9 billion revenue and $1.80 adjusted EPS, driven by Bioprocessing growth, and updated full-year guidance [Financial & Operational Highlights](index=1&type=section&id=Key%20Second%20Quarter%202025%20Results) Danaher exceeded Q2 2025 expectations with 3.5% revenue growth to $5.9 billion and $1.80 adjusted diluted EPS, driven by Bioprocessing - CEO Rainer M. Blair credited the strong quarterly performance to the Danaher Business System, robust growth in the Bioprocessing business, and disciplined cost management[2](index=2&type=chunk) Q2 2025 Key Financial Metrics | Metric | Value | YoY Change | | :--- | :--- | :--- | | Revenues | $5.9 billion | +3.5% | | Non-GAAP Core Revenue | - | +1.5% | | Net Earnings | $555 million | - | | Diluted EPS (GAAP) | $0.77 | - | | Adjusted Diluted EPS (Non-GAAP) | $1.80 | - | | Operating Cash Flow | $1.3 billion | - | | Free Cash Flow (Non-GAAP) | $1.1 billion | - | [Business Outlook for Q3 and Full Year 2025](index=1&type=section&id=Third%20Quarter%20and%20Full%20Year%202025%20Outlook) Danaher projects low-single-digit core revenue growth for Q3 2025, maintains 3% full-year core revenue outlook, and raises full-year adjusted diluted EPS guidance to $7.70-$7.80 - For Q3 2025, the company anticipates non-GAAP core revenue to grow in the low-single digits year-over-year[4](index=4&type=chunk) - The full-year 2025 non-GAAP core revenue growth expectation remains unchanged at approximately **3%** year-over-year[4](index=4&type=chunk) - The company increased its full-year 2025 adjusted diluted net earnings per common share guidance to a new range of **$7.70 to $7.80**, up from the previous guidance of $7.60 to $7.75[4](index=4&type=chunk) [Financial Statements](index=3&type=section&id=Financial%20Statements) This section presents unaudited Consolidated Condensed Statements of Earnings for Q2 and H1 2025, detailing sales, costs, and net earnings [Consolidated Condensed Statements of Earnings](index=3&type=section&id=CONSOLIDATED%20CONDENSED%20STATEMENTS%20OF%20EARNINGS) Danaher's Q2 2025 sales rose to $5.94 billion, but increased SG&A led to a decline in operating profit to $760 million and net earnings to $555 million Q2 Financial Performance Comparison ($ in millions) | Metric | Q2 2025 | Q2 2024 | | :--- | :--- | :--- | | Sales | $5,936 | $5,743 | | Gross Profit | $3,523 | $3,428 | | Operating Profit | $760 | $1,168 | | Net Earnings | $555 | $907 | | Diluted EPS | $0.77 | $1.22 | First Half Financial Performance Comparison ($ in millions) | Metric | H1 2025 | H1 2024 | | :--- | :--- | :--- | | Sales | $11,677 | $11,539 | | Gross Profit | $7,034 | $6,915 | | Operating Profit | $2,034 | $2,480 | | Net Earnings | $1,509 | $1,995 | | Diluted EPS | $2.10 | $2.68 | [Non-GAAP Financial Measures & Reconciliations](index=4&type=section&id=RECONCILIATION%20OF%20GAAP%20TO%20NON-GAAP%20FINANCIAL%20MEASURES) This section reconciles GAAP to non-GAAP financial measures, including EPS, sales growth by segment, and free cash flow, explaining their utility for investors [Reconciliation of GAAP to Non-GAAP EPS](index=4&type=section&id=Diluted%20Net%20Earnings%20Per%20Common%20Share%20and%20Adjusted%20Diluted%20Net%20Earnings%20Per%20Common%20Share) Danaher reconciles Q2 2025 GAAP Diluted EPS of $0.77 to Non-GAAP Adjusted Diluted EPS of $1.80, primarily due to amortization and impairment charges Q2 2025 EPS Reconciliation (GAAP to Non-GAAP) | Description | Per Share Amount | | :--- | :--- | | **Diluted Net Earnings Per Common Share (GAAP)** | **$0.77** | | Amortization of acquisition-related intangible assets | $0.59 | | Fair value net losses on investments | $0.06 | | Impairments | $0.60 | | Tax effect of adjustments & discrete tax items | ($0.23) | | **Adjusted Diluted Net Earnings Per Common Share (Non-GAAP)** | **$1.80** | - Impairment charges in Q2 2025 included a **$432 million** pretax charge related to a trade name in the Life Sciences segment[20](index=20&type=chunk) [Sales Growth by Segment](index=5&type=section&id=Sales%20Growth%20(Decline)%20by%20Segment%20and%20Core%20Sales%20Growth%20(Decline)%20by%20Segment) Q2 2025 saw Biotechnology lead with 8.0% total sales growth, while Life Sciences experienced a core sales decline, contributing to 3.5% total company sales growth Q2 2025 % Sales Growth vs. Q2 2024 | Segment | Total Sales Growth (GAAP) | Core Sales Growth (Non-GAAP) | | :--- | :--- | :--- | | Biotechnology | 8.0% | 6.0% | | Life Sciences | 0.5% | (2.5)% | | Diagnostics | 2.0% | 2.0% | | **Total Company** | **3.5%** | **1.5%** | H1 2025 % Sales Growth vs. H1 2024 | Segment | Total Sales Growth (GAAP) | Core Sales Growth (Non-GAAP) | | :--- | :--- | :--- | | Biotechnology | 7.0% | 6.5% | | Life Sciences | (1.5)% | (3.5)% | | Diagnostics | (0.5)% | 0.0% | | **Total Company** | **1.0%** | **1.0%** | [Cash Flow Reconciliation](index=6&type=section&id=Cash%20Flow%20and%20Free%20Cash%20Flow) Danaher's Q2 2025 operating cash flow was $1.34 billion, resulting in non-GAAP free cash flow of $1.09 billion after capital expenditures Free Cash Flow Calculation ($ in millions) | Metric | Q2 2025 | Q2 2024 | | :--- | :--- | :--- | | Net cash provided by operating activities (GAAP) | $1,338 | $1,417 | | Less: Capital expenditures (GAAP) | ($248) | ($287) | | Plus: Capital disposals (GAAP) | $4 | $1 | | **Free cash flow (non-GAAP)** | **$1,094** | **$1,131** | [Statement Regarding Non-GAAP Measures](index=7&type=section&id=Statement%20Regarding%20Non-GAAP%20Measures) Management uses non-GAAP measures like core sales and adjusted EPS to assess performance and profitability by excluding volatile items for consistent comparisons - Management uses non-GAAP measures to assess operating performance, understand long-term profitability trends, identify underlying growth, and evaluate the ability to generate cash[28](index=28&type=chunk)[29](index=29&type=chunk) - Key items excluded from non-GAAP measures include amortization of acquisition-related intangible assets, discrete restructuring charges, currency translation effects, and the impact of acquisitions and divestitures to facilitate more consistent comparisons[29](index=29&type=chunk) [Other Information](index=1&type=section&id=Other%20Information) This section provides details for the investor conference call and webcast, alongside the standard forward-looking statements disclaimer [Conference Call and Webcast Information](index=1&type=section&id=Conference%20Call%20and%20Webcast%20Information) An investor conference call and webcast are scheduled for July 22, 2025, at 8:00 a.m. ET to discuss Q2 results and guidance - An investor conference call to discuss Q2 results and guidance is scheduled for **8:00 a.m. ET** on the day of the release[5](index=5&type=chunk) - Webcast, presentation slides, and replay information are available on the 'Investors' section of Danaher's website[5](index=5&type=chunk)[6](index=6&type=chunk) [Forward-Looking Statements](index=2&type=section&id=FORWARD-LOOKING%20STATEMENTS) This legal disclaimer cautions that forward-looking statements, including financial guidance, are subject to significant risks and uncertainties that could alter actual results - The release contains forward-looking statements, including financial guidance for Q3 and the full year 2025, which are not guarantees of future performance[12](index=12&type=chunk) - A number of factors could cause actual results to differ materially, including global economic conditions, competition, ability to integrate acquisitions, and geopolitical risks[12](index=12&type=chunk)

Core Viewpoint - The article discusses the current state of the US stock market, highlighting a bullish sentiment driven by factors such as corporate buybacks, retail investor activity, and strong capital flows, while also addressing potential risks of a market correction in the near future [4][12][39]. Group 1: Market Sentiment and Predictions - Scott Rubner from Citadel Securities believes the bull market has not peaked yet, with a positive outlook for the next month due to corporate buybacks, continued retail buying, and ample institutional holdings [6][9]. - Historical data shows that July has been the best month for the S&P 500 since 1928, while September tends to be weaker, suggesting a favorable environment for stocks in July [9]. - Retail investors have been net buyers for 14 consecutive trading days, marking the longest streak since December of the previous year, with their holdings reaching 20% of the market [9][18]. Group 2: Corporate Buybacks and Retail Investor Activity - Corporate buybacks are expected to reach $1 trillion by 2025, with a significant increase in buyback activity anticipated after August, providing strong support for stock prices [9][21]. - The summer months are traditionally a peak period for corporate buybacks, which will likely contribute to demand in the market [21]. - Retail investors have contributed significantly to market momentum, with net inflows of $155 billion into stocks and ETFs this year, representing nearly 60% of household financial assets when including indirect holdings [18][39]. Group 3: Diverging Views Among Analysts - Michael Hartnett from Bank of America warns of increased short-term correction risks, citing that all sell signals have been triggered and the market is entering a "danger zone" [12][14]. - Hartnett highlights a concerning concentration of market strength among a few tech giants, which could lead to volatility if economic or policy conditions change [14][25]. - The current market breadth is insufficient, with a significant disparity between large-cap tech stocks and small-cap/value stocks, reminiscent of the 2000 tech bubble [25]. Group 4: Sector Focus and Investment Opportunities - The AI sector remains a hot topic, with major companies like NVIDIA, Microsoft, and Tesla expected to drive technological innovation in the second half of the year [31]. - The pharmaceutical and biotech sectors are also gaining attention, particularly gene editing technologies like CRISPR, which are seen as promising for extending human lifespan [34]. - Investors are advised to focus on innovation pipelines and core product launches while being cautious of high volatility and speculative growth stories in the biotech space [37]. Group 5: Overall Market Outlook - The US stock market is expected to maintain a strong rebound in the short term, with structural opportunities present, particularly in tech and biotech sectors [39]. - However, investors should remain vigilant for potential corrections as market sentiment heats up, with recommendations to increase hedging strategies as September approaches [39][42]. - The article emphasizes the importance of balancing aggressive investment strategies with profit protection to navigate the market effectively [42].

Core Insights - Danaher Corporation (DHR) is set to release its second-quarter 2025 results on July 22, before market open [1] Revenue Estimates - The Zacks Consensus Estimate for revenues is $5.84 billion, reflecting a 1.6% increase from the same quarter last year [2] - The consensus estimate for earnings is $1.64 per share, indicating a 4.7% decrease from the year-ago quarter [2] Segment Performance - The Life Sciences segment is expected to see a revenue decline of 3.4% to $1.71 billion due to weak demand in protein consumables, flow cytometry, and lab automation solutions [3] - The Biotechnology segment is projected to grow by 7% to $1.83 billion, driven by increased demand for bioprocessing consumables from large pharmaceutical customers [5] - The Diagnostics segment is anticipated to increase by 1.1% to $2.29 billion, supported by solid momentum in pathology and acute care diagnostics [6] Cost and Expenses - SG&A expenses are expected to rise by 5.8% to $1.55 billion, which may negatively impact the bottom line [4] - Foreign currency headwinds are likely to affect profitability due to significant international operations [4] Recent Developments - Danaher acquired Abcam plc in December 2023, enhancing its Life Sciences segment with a strong product portfolio and innovation capabilities [7] Earnings Prediction - The Earnings ESP for DHR is 0.00%, indicating no clear prediction for an earnings beat this quarter [9] - The company currently holds a Zacks Rank of 4 (Sell) [11]

Core Insights - Danaher (DHR) is expected to report quarterly earnings of $1.64 per share, a decline of 4.7% year-over-year, with revenues forecasted at $5.84 billion, reflecting a 1.6% increase compared to the previous year [1] Earnings Estimates - The consensus EPS estimate has not changed over the past 30 days, indicating analysts have maintained their projections [2] - Revisions to earnings estimates are crucial for predicting investor actions, as there is a strong correlation between earnings estimate trends and short-term stock performance [3] Key Metrics Forecast - Analysts project 'Total sales- Diagnostics' at $2.28 billion, a year-over-year increase of 1.1% [5] - 'Total sales- Life Sciences' is expected to be $1.71 billion, indicating a decline of 3.5% year-over-year [5] - 'Total sales- Biotechnology' is forecasted at $1.83 billion, reflecting a year-over-year increase of 6.8% [5] Operating Profit Estimates - The consensus for 'Operating profit- Life Sciences' is $206.51 million, down from $233.00 million in the same quarter last year [6] - 'Operating profit- Biotechnology' is estimated at $463.69 million, slightly up from $462.00 million year-over-year [6] - 'Operating profit- Diagnostics' is projected to be $501.31 million, down from $556.00 million in the previous year [7] Stock Performance - Danaher shares have decreased by 0.6% over the past month, while the Zacks S&P 500 composite has increased by 4.2% [7] - With a Zacks Rank of 4 (Sell), Danaher is expected to underperform the overall market in the near term [7]

Core Viewpoint - The merger between BD and Waters aims to create a new leader in the life sciences and diagnostics sector, targeting the expanding precision medicine and biopharmaceutical markets with a total transaction value of approximately $17.5 billion [1][4][17]. Recent Developments and Future Outlook - In February 2025, BD announced plans to divest its biosciences and diagnostics business, followed by the merger agreement with Waters on July 14, 2025, with completion expected by the end of Q1 2026, pending regulatory approval [3]. - The global life sciences instrument market is projected to reach $85 billion by 2030, with a CAGR of approximately 5-6%, highlighting significant growth opportunities in precision medicine, biopharmaceuticals, and multiplex diagnostics [3]. Strategic Motives - The transaction reflects a strategic shift for both companies: BD focuses on core medical technologies, while Waters seeks to transform its business model from single instrument sales to recurring revenue in diagnostics and services [4][5]. - BD's divestiture aligns with its strategy to concentrate resources on core products like syringes and smart medical devices, which are closely tied to hospital workflows [4][7]. Industry Landscape and Market Opportunities - The merger occurs in a competitive environment where major players like Thermo Fisher and Danaher have expanded through acquisitions, creating pressure on mid-sized analytical instrument companies [5]. - The new company is expected to leverage BD's established presence in Asia, particularly in China and Japan, to enhance global expansion potential [3]. Technical Complementarity - The merger is significant for its technical complementarity, enabling a full chain capability from molecular analysis to cellular detection, which is crucial for biopharmaceutical development and personalized medicine [9][10]. Synergies and Collaborative Value - BD and Waters anticipate achieving approximately $200 million in cost synergies and $290 million in revenue synergies post-merger, but the focus is on the broader industry collaborative value rather than just financial metrics [11]. - The integration of technologies and market strategies is expected to enhance their competitive edge in the life sciences sector [12][16]. Product and Service Integration - The combined entity will offer a comprehensive solution that integrates molecular diagnostics and analytical capabilities, addressing the full spectrum of biopharmaceutical research and clinical validation needs [15]. - The merger allows for the development of complex multiplex testing products, enhancing diagnostic speed and accuracy [15]. Conclusion - The merger between BD and Waters represents a transformative move in the life sciences and diagnostics industry, positioning the new company as a key player in advancing precision medicine and biopharmaceutical innovation [17].

Core Viewpoint - Danaher (NYSE: DHR) is expected to experience strong growth, particularly in its Biotech segment, which is benefiting from double-digit growth in consumables [1] Group 1: Company Performance - The Biotech segment is showing good momentum, driven by significant growth in consumables [1] - Equipment orders are beginning to recover, with expectations for equipment revenues to return to growth [1] Group 2: Investment Strategy - The focus is on GARP (Growth at Reasonable Price) opportunities within the industrial, consumer, and technology sectors [1]

Core Viewpoint - Danaher Corporation is enhancing its digital transformation by appointing Martin Stumpe as Chief Technology and AI Officer, effective October 1, 2025, to lead the integration of AI across its global businesses [1][2][3]. Group 1: Appointment and Leadership - Martin Stumpe will report directly to Rainer Blair, President and CEO, marking a significant step in Danaher's ambition to lead innovation in life sciences and diagnostics [1][2]. - Stumpe's previous experience includes serving as Chief Data and AI Officer at Tempus and founding the Cancer Pathology project at Google, showcasing his expertise in AI and healthcare [3]. Group 2: Strategic Goals - Under Stumpe's leadership, Danaher aims to accelerate the integration of AI, enhancing scientific discovery, operational efficiency, and clinical impact [2][3]. - The company is committed to leveraging science, data, and technology to improve human health, emphasizing the importance of innovation in addressing health challenges globally [3][4]. Group 3: Company Overview - Danaher is recognized as a leading global innovator in life sciences and diagnostics, with a workforce of 63,000 associates dedicated to improving quality of life and developing life-changing therapies [4]. - The company focuses on scientific excellence and continuous improvement to enable faster and more accurate diagnoses, ultimately reducing the time and cost of therapy development [4].